CorMedix Inc (CRMD.A)

CRMD.A

About

CorMedix Inc. (CorMedix) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease. The Company has licensed all of the products in its Cardiorenal pipeline. The Company has several product... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.26
Market Cap (Mil.):	$2.51
Shares Outstanding (Mil.):	11.41
Dividend:	--
Yield (%):	--

Financials

	CRMD.A	Industry	Sector
P/E (TTM):	--	16.62	43.38
EPS (TTM):	-0.49	--	--
ROI:	-194.27	5.53	9.53
ROE:	-195.28	8.36	11.11

Latest News about CRMD.A

» More CRMD.A News

Earnings vs Estimates

Analyst Research Reports

Report Title	Price
CORMEDIX INC (CRMD) 2-weeks forecast Provider: Pechala's Reports	$10.00 Buy
CorMedix Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
CorMedix, Inc. (CRMD) - Financial Analysis Review Provider: GlobalData	$253.00 Buy
CORMEDIX INC (CRMD) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
CorMedix Inc.-Therapeutic Competitors Provider: Life Science Analytics	$350.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Africa
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.